Nasser Khan

机构：Daiichi Sankyo (Germany), AbbVie (United States), Daiichi-Sankyo (South Korea)

发表论文 31 篇 · 总被引 1453 次 · h-index 14

代表论文

• Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis (2020 · New England Journal of Medicine · 被引 308)
• Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme (2020 · Annals of the Rheumatic Diseases · 被引 238)
• Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study (2022 · RMD Open · 被引 104)
• Incidence and risk factors for herpes zoster in patients with rheumatoid arthritis receiving upadacitinib: a pooled analysis of six phase III clinical trials (2022 · Annals of the Rheumatic Diseases · 被引 88)
• ABT ‐122, a Bispecific Dual Variable Domain Immunoglobulin Targeting Tumor Necrosis Factor and Interleukin‐17A, in Patients With Rheumatoid Arthritis With an Inadequate Response to Methotrexate (2018 · Arthritis & Rheumatology · 被引 77)
• Safety, Tolerability, and Pharmacodynamics of ABT ‐122, a Tumor Necrosis Factor– and Interleukin‐17–Targeted Dual Variable Domain Immunoglobulin, in Patients With Rheumatoid Arthritis (2017 · Arthritis & Rheumatology · 被引 32)